Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis by X. Jia et al.
RESEARCH ARTICLE
Genome Sequencing Uncovers
Phenocopies in Primary Progressive
Multiple Sclerosis
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Objective: Primary progressive multiple sclerosis (PPMS) causes accumulation of neurological disability from disease
onset without clinical attacks typical of relapsing multiple sclerosis (RMS). However, whether genetic variation influen-
ces the disease course remains unclear. We aimed to determine whether mutations causative of neurological disor-
ders that share features with multiple sclerosis (MS) contribute to risk for developing PPMS.
Methods: We examined whole-genome sequencing (WGS) data from 38 PPMS and 81 healthy subjects of European
ancestry. We selected pathogenic variants exclusively found in PPMS patients that cause monogenic neurological dis-
orders and performed two rounds of replication genotyping in 746 PPMS, 3,049 RMS, and 1,000 healthy subjects.
To refine our findings, we examined the burden of rare, potentially pathogenic mutations in 41 genes that cause
hereditary spastic paraplegias (HSPs) in PPMS (n5 314), secondary progressive multiple sclerosis (SPMS; n5 587),
RMS (n5 2,248), and healthy subjects (n5987) genotyped using the MS replication chip.
Results: WGS and replication studies identified three pathogenic variants in PPMS patients that cause neurological
disorders sharing features with MS: KIF5A p.Ala361Val in spastic paraplegia 10; MLC1 p.Pro92Ser in megalencephalic
leukodystrophy with subcortical cysts, and REEP1 c.606143G>T in Spastic Paraplegia 31. Moreover, we detected a
significant enrichment of HSP-related mutations in PPMS patients compared to controls (risk ratio [RR] 5 1.95; 95%
confidence interval [CI], 1.27–2.98; p5 0.002), as well as in SPMS patients compared to controls (RR5 1.57; 95% CI,
1.18–2.10; p5 0.002). Importantly, this enrichment was not detected in RMS.
Interpretation: This study provides evidence to support the hypothesis that rare Mendelian genetic variants contrib-
ute to the risk for developing progressive forms of MS.
ANN NEUROL 2017;00:000–000
Primary progressive multiple sclerosis (PPMS) is a rareform of multiple sclerosis (MS) characterized by pro-
gressive accumulation of disability from disease onset
without the attacks typically observed in the relapsing
form of the disease (RMS).1 PPMS represents an unmet
need in the care of neurological patients because of its
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poor response to MS disease-modifying therapies and its
relentless clinical course that resembles neurodegenerative
disorders.2 Compared to RMS, PPMS patients are older
at onset, men and women are equally affected, and the
most common clinical presentation is a progressive spas-
tic paraparesis.3,4 Moreover, some family studies demon-
strate a higher concordance in MS disease course (PPMS
versus RMS) within affected siblings than expected by
chance.5–7 These observations suggest that unique genetic
and environmental susceptibility factors may, in part,
influence risk for PPMS.
To date, genetic studies have not shown a difference
between PPMS and RMS susceptibility,8 either because
of a strong shared genetic susceptibility or because of a
lack of power given the lower prevalence of primary pro-
gressive disease and consequent under-representation in
genome-wide association studies (GWAS) and other
screens. Furthermore, the role of Mendelian genes has
not been systematically studied in MS, despite the obser-
vation that there is widespread comorbidity among
Mendelian and complex diseases.9 PPMS shares clinical
features with specific Mendelian neurological disorders
(ie, potential MS phenocopies) that cause progressive
neurological disability attributed to injury to the central
nervous system (CNS). Examples of genetic disorders
that resemble PPMS include hereditary spastic paraple-
gias (HSPs), inherited leukodystrophies, and mitochon-
drial disorders.3,10,11
This study aims to determine whether mutations
causative of genetic disorders that share features with MS
contribute to disability in PPMS. Furthermore, we
hypothesized that genomes from subjects with PPMS are
enriched for mutations in genes involved in monogenic
disorders that share clinicopathological features of MS.
To this end, we performed whole-genome sequencing
(WGS) in a well-characterized PPMS cohort and vali-
dated identified variants in multiple independent PPMS
cohorts. We next examined whether PPMS patients car-
ried mutations in specific classes of MS phenocopy disor-
ders. Specifically, we hypothesized that PPMS patients
TABLE 1. Demographic Data in Study Cohorts Used to Identify MS Phenocopy Mutations
Discovery Phase Phase 1 Replication Phase 2 Replication
Platform Complete Genomics Inc. Illumina OpenArray Targeted Genotyping
Variants 15.2 million 15 4
Cohort
source
UCSF 1KGa (64),
CGIb (11),
UCSF (6)
Germany UCSF Italy UCSF
Phenotype PPMSc Controls PPMS PPMS RMS PPMS RMS RMS Controls
Sample size 38 81 142 269 460 335 340 2,249 1,000
Age at onset
Mean 6 SD 42.9 6 9.9 NA — 40.1 6 11.1 31.2 6 9.2 40.7 6 9.5 29.5 6 9.4 31.9 6 9.5 NA
Median
(range)
47 (25–54) NA — 40 (5–66) 31 (4–61) 40 (18–66) 28 (10–64) 31 (5–69) NA
Disease
duration
Mean 6 SD 11.3 6 8.1 NA — 19.2 6 11.3 22.6 6 9.9 11.1 6 7.3 9.0 6 5.3 13.8 6 10.6 NA
Median
(range)
10 (0–37) NA — 18 (1–56) 20 (10–62) 10 (1–45) 8 (1–39) 12 (0–66) NA
Female
sex (%)
22 (58) 39 (48) 93 (65) 155 (58) 475 (60) 171 (50.6) 179 (52.6) 1,886 (84) 516 (52)
a1000 Genomes Project, Complete Genomics Data.
bComplete Genomics Inc. Public Genomes.
cPatients meet 2010 International Panel Criteria for PPMS.
MS5multiple sclerosis; SD5 standard deviation; UCSF5University of California San Francisco; PPMS5primary progressive multiple sclerosis;
NA5 not applicable; HSP5 hereditary spastic paraplegia; PPMS5primary progressive multiple sclerosis; RMS5 relapsing multiple sclerosis.
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were enriched for mutations in genes that caused heredi-
tary spastic paraplegias, a rare group of conditions that
cause progressive leg weakness and spasticity resembling
PPMS.12 Last, we performed similar analyses in RMS
and secondary progressive multiple sclerosis (SPMS)
patients to determine whether MS phenocopy mutations
identified in this study were unique to PPMS.
Patients and Methods
Cohorts
All human studies were approved by each respective institu-
tional ethics review committee, and all participants provided
written informed consent. To investigate the role of MS pheno-
copy mutations in PPMS pathogenesis, we examined WGS
data in a discovery cohort of 38 PPMS patients of European
descent and 81 ethnicity-matched controls. PPMS patients in
this group were recruited at or referred to the University of
California San Francisco (UCSF) between 1996 and 2013 and
satisfied 2010 International Panel Criteria13 (Table S1). WGS
data for controls were obtained from the 1000 Genomes Pro-
ject,14 Complete Genomics Inc. (CGI) Public Genomes,15 and
healthy individuals recruited at UCSF. We subsequently per-
formed replication genotyping in 142 PPMS patients from Ger-
many and in 269 PPMS and 460 RMS patients recruited at
UCSF (Phase 1 replication). We performed a second round of
replication in 335 PPMS and 340 RMS patients from Italy and
in 2,249 RMS patients and 1,000 healthy controls recruited at
UCSF (Phase 2 replication). In total, the discovery and replica-
tion cohorts included 784 PPMS and 3,049 RMS patients and
1,081 controls (Table T11; Fig F11A).
To test the hypothesis that PPMS patients may be
enriched for mutations in genes that cause spastic paraplegias,
we examined a cohort of 48 PPMS patients of European
descent recruited at UCSF and 100 ethnicity-matched controls
who were genotyped using the MS replication chip.16 These
PPMS patients met 2010 International Panel Criteria and
included 25 patients from our WGS cohort and 23 patients
FIGURE 1: Summary of study cohorts, genotyping platforms, and variant selection. (A) Schematic of study design used for iden-
tifying MS phenocopy variants. The WGS discovery cohort included 38 PPMS patients (who met 2010 International Panel Crite-
ria) and 81 ethnicity-matched controls sequenced using the Complete Genomics Inc. (CGI) platform. Fifteen candidate variants
were selected for Phase 1 replication genotyping in 411 PPMS and 460 RMS patients using OpenArray. Four top candidate
variants exclusively found in PPMS and not RMS patients were selected for Phase 2 replication in 335 PPMS and 340 RMS
patients from an Italian cohort and in 2,249 RMS and 1,000 controls from UCSF. (B) Schematic of study design used for deter-
mining the burden of HSP-related mutations in PPMS. The discovery cohort comprised of 48 PPMS patients (who met 2010
International Panel Criteria) and 100 controls genotyped on the MS replication chip. Replication patients included an additional
266 PPMS, 1,702 RMS, and 887 control subjects from three additional cohorts (NARCOMS, Australian, and Italian) genotyped
on the same platform. All subjects examined were of European ancestry. CADD5Combined Annotation Dependent Depletion;
CNS5 central nervous system; GWAS5genome-wide association studies; HGMD5Human Gene Mutation Database;
HSP5hereditary spastic paraplegia; MS5multiple sclerosis; NARCOMS5North America Research Committee on Multiple
Sclerosis; PhyloP5phylogenetic conservation p value; PPMS5primary progressive multiple sclerosis; RMS5 relapsing multiple
sclerosis; SNVs5 single-nucleotide variants; SPMS5 secondary progressive multiple sclerosis; UCSF5University of California
San Francisco; WGS5whole-genome sequencing.
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who were exclusively genotyped on the MS chip (Table S1).
For replication, we examined three additional cohorts of Euro-
pean ancestry genotyped on the same platform. These included
the North America Research Committee on Multiple Sclerosis
(NARCOMS; 122 PPMS and 321 controls), an Australian
cohort (57 PPMS and 410 controls), and an Italian cohort (87
PPMS and 156 controls). Last, we examined RMS and SPMS
patients from these cohorts to investigate whether MS pheno-
copy mutations are unique to patients with PPMS. In total, we
performed enrichment analysis in 314 PPMS, 587 SPMS,
2,248 RMS, and 987 healthy subjects (TableT2 2; Fig 1B). A
description of all cohorts and genotyping methods is provided
in Tables 1 and 2 and Figure 1.
WGS and Replication Genotyping
For each sample selected for genome sequencing, we derived
lymphoblastoid cell lines (LCLs) from whole blood samples17
and extracted 15lg of DNA from each of these cell lines for
sequencing using the CGI platform.15 The LCL is a convenient
research tool for obtaining virtually unlimited amounts of bio-
logical material from an individual, and there is high
concordance for single-nucleotide variant (SNV) calls obtained
from WGS using LCL and whole blood.18 CGI performed
DNA read mapping to the human genome (reference hg19)
and provided variant calls using CGI proprietary software.19
We performed additional quality control by removing low-
quality calls (heterozygous calls with VarScoreVAF <40 and
homozygous calls with VarScoreVAF <20) and variants with
less than 95% call rate. We confirmed European ancestry using
Identity-By-Descent analysis of WGS variants.20 We annotated
WGS variants with curated data from the Human Gene Muta-
tion Database21,22 (HGMD) and selected SNVs that were func-
tionally deleterious (nonsynonymous exonic, splice site, or
mRNA binding site), rare (<1% in public cohorts), classified
as pathogenic, affected monogenic neurological disorders, and
were exclusively found in PPMS patients. We used an allele fre-
quency cutoff of 1% to identify potentially pathogenic muta-
tions, which, in Mendelian disorders, have allele frequencies
below 0.1%.23 Candidate MS phenocopy variants were then
selected for replication genotyping using the Illumina OpenAr-
ray system (Illumina, San Diego, CA) in Phase 1 replication
and using targeted individual genotyping in Phase 2 replication.
TABLE 2. Discovery and Replication Cohorts Used to Examine Burden of Spastic Paraplegia Mutations
Discovery Cohort Replication Cohort 1 Replication Cohort 2 Replication Cohort 3
Platform MS Replication Chip MS Replication Chip MS Replication Chip MS Replication Chip
Variants 331,536 169a 169a 169a
Cohort UCSF NARCOMSb Australia Italy
Diagnosisd CTL RMS SPMS PPMS CTL RMS SPMS PPMS CTL RMS SPMS PPMS CTL RMS SPMS PPMS
Samples 100 930 203 48c 321 586 222 122 410 452 75 57c 156 280 87 87
Age at
onset
Mean
6 SD
NA 32.8
6 9.4
31.3
6 9.3
42.3
6 11.2
NA 32.6
6 9.8
31.0
6 9.2
40.7
6 11.1
NA 36
6 9.8
35
6 9.4
42
6 10.8
NA 28.2
6 8.9
29.1
6 9.4
39.9
6 10.1
Median,
range
NA 32
(5–64)
31
(11–58)
42
(22–66)
NA 33
(4–61)
30
(10–65)
41
(12–66)
NA 36
(14–64)
33
(15–59)
41
(20–72)
NA 27
(7–52)
27
(15–59)
40
(19–60)
Disease
duration
Mean
6 SD
NA 12.6
6 9.5
23.0
6 10.0
11.2
6 7.4
NA 21.9
6 11.3
28
6 10.9
22.6
6 10.4
NA 8
6 6.5
21
6 10.2
13
6 9.9
NA 8.1
6 7.0
17.3
6 7.9
10.8
6 8.2
Median
range
NA 12
(0–54)
22
(3–48)
10
(0–37)
NA 20
(1–66)
28
(0–58)
20
(2–56)
NA 6
(0–41)
22
(3–44)
10
(1–43)
NA 6
(0–37)
17
(3–41)
9
(1–45)
Female
sex
22% 74% 68% 40% 47% 81% 81% 61% 77% 77% 76% 61% 38% 66% 70% 57%
aOne hundred sixty-nine HSP-related variants were examined in these replication cohorts.
bNorth American Research Committee on Multiple Sclerosis.
cPatients met 2010 International Panel Criteria for PPMS.
dCTL5 control subjects; RMS5 relapsing MS patients excluding those with known secondary progression; SPMS5 secondary progressive MS;
PPMS5primary progressive MS.
SD5 standard deviation; UCSF5University of California San Francisco; NA5 not applicable; HSP5 hereditary spastic paraplegia.
J_ID: ANA Customer A_ID: ANA25263 Cadmus Art: ANA25263 Ed. Ref. No.: 17-1506.R3 Date: 23-June-18 Stage: Page: 4
ID: jwweb3b2server Time: 20:39 I Path: //chenas03.cadmus.com/Cenpro/ApplicationFiles/Journals/Wiley/ANA#/Vol00000/180111/Comp/APPFile/JW-ANA#180111
ANNALS of Neurology
4 Volume 00, No. 0054 Volume 84, No. 1
l gy
Mutation Enrichment Analysis
To determine whether PPMS patients are enriched for muta-
tions in genes that cause spastic paraplegias, we examined cases
and controls who were genotyped using the custom MS replica-
tion chip, which includes 88,635 autoimmune markers and
242,910 exonic variants from the Illumina HumanExome Bead-
Chip v1.1. Quality control included the following SNV-level
exclusion criteria: (1) missingness> 0.05; (2) Hardy-Weinberg
equilibrium p value< 1026; and (3) differential missingness in
cases and controls p value< 0.001. We annotated variants using
Ingenuity Variant Analysis24 and extracted all rare (minor allele
frequency [MAF]< 1% in public data sets), functionally delete-
rious (missense and splice site), and potentially pathogenic
(Combined Annotation Dependent Depletion [CADD] score-
> 10; Phylogenetic conservation p value [PhyloP]< 0.01) var-
iants within 41 genes that cause spastic paraplegias (Table
S4).12,25–29 We performed logistic regression on the number of
potentially pathogenic variants per individual adjusted for sub-
ject sex and used p5 0.05 as the threshold for significance. To
understand the impact of variant selection on enrichment
results, we performed sensitivity analysis using different in silico
predicted pathogenicity scores including CADD, PhyloP, Sort-
ing Intolerant From Tolerant (SIFT), and Polymorphism Geno-
typing v2 [PolyPhen-2]; Table S5). To evaluate the likelihood
of finding an enrichment of spastic paraplegia variants in
PPMS patients by chance, we randomly permuted PPMS and
healthy control status in our discovery cohort 10,000 times and
determined the permutation p value as the likelihood of observ-
ing an enrichment in HSP-related genes greater than or equal
to that found in our discovery cohort.
To replicate our findings from mutation enrichment analy-
sis, we examined the same spastic paraplegia variants in three addi-
tional PPMS cohorts genotyped on the MS replication chip. We
performed meta-analysis across these four (discovery plus three rep-
lication) cohorts using a random-effects model examining the
mean number of mutations per individual in PPMS compared to
controls. To determine whether the enrichment of HSP-related
mutations is unique to PPMS, we also examined RMS and SPMS
patients genotyped on the MS replication chip from these four
cohorts. We calculated the average number of spastic paraplegia
variants per individual in each phenotype and used a t test to deter-
mine whether the average burden of HSP-related variants differed
between MS disease-course subtypes.
To investigate the relationship between spastic paraplegia
variants and the burden of common MS susceptibility variants,
we calculated the MS Genetic Burden (MSGB) using MS replica-
tion chip genotypes. The MSGB is obtained by summing the
number of independently associated MS risk alleles weighted by
their beta coefficients, obtained from a large GWAS meta-
analysis, at 177 (of 200) non-MHC (major histocompatibility
complex) loci and 18 (of 32) MHC variants, which includes the
HLA-DRB1*15:01-tagging single-nucleotide polymorphism
(SNP) rs3135388.16 Subsequently, we examined whether the
average MSGB differed between PPMS (n5 170), SPMS
(n5 425), RMS (n5 1516), and healthy subjects (n5 421) in
the UCSF and NARCOMS cohorts using pair-wise t tests
between groups. Finally, we examined whether the mean MSGB
differed in PPMS and SPMS patients who carried a HSP-related
variant compared to those who did not carry any such variants.
Results
Genome sequencing in a well-characterized cohort of 38
PPMS patients and 81 ethnicity-matched controls using
CGI yielded on average greater than 503 depth of cover-
age and identified more than 3 million SNVs, 5,000 inser-
tion deletions, 1,500 structural variants, and 250 copy
number variants (CNVs) per sample. After performing
quality control, we found 14,709,637 high-quality SNV
calls in the autosomal and sex chromosomes across these
119 genomes that comprised our discovery cohort (Fig 1).
We searched for candidate MS phenocopy variants,
by annotating the 14.7 million SNVs identified in the
119 genomes, and found 1,287 pathogenic variants
directly involved in 714 Mendelian disorders. Of these,
691 variants involved in 474 disorders were identified in
PPMS patients, and 1,029 variants involved in 609 dis-
orders were identified in controls. This included 52 var-
iants on the sex chromosomes; however, none of these
affected neurological disorders that share features with
MS. Fifteen of the 691 variants found in PPMS patients
were rare, functionally deleterious, affected neurological
disorders and were absent in controls. We attempted an
independent replication to validate the WGS calls in the
discovery cohort by genotyping these 15 variants in an
additional 411 PPMS and 460 RMS patients using the
Illumina OpenArray platform (Phase 1 replication).
Twelve of the 15 candidate variants were confirmed, and
four were exclusively found in PPMS (and not in RMS)
patients in the combined discovery and initial replication
cohort. To further assess whether these four pathogenic
variants were PPMS specific, we selectively genotyped
them in an additional set of PPMS (n5 335) and RMS
(n5 2,589) patients, in addition to healthy subjects
(n5 1,000; Phase 2 replication). The variants selected
for replication genotyping are summarized in Table T33.
The four variants selected for Phase 2 replication
were observed at a higher frequency in PPMS patients
(n5 784) compared to over 36,000 European individuals
from the Exome Aggregation Consortium (ExAC-
EUR).30 Of note, three of these variants had been previ-
ously reported in disorders that potentially mimic MS:
KIF5A p.Ala361Val (risk ratio [RR]5 23), a dominant
variant for spastic paraplegia 10 (SPG10 [MIM:
604187])27; MLC1 p.Pro92Ser (RR5 1.8), a recessive
variant for megalencephalic leukodystrophy with subcor-
tical cysts (MLC [MIM: 604004])31; and REEP1
c.6061 43G>T (RR5 1.6), a dominant variant affecting
mRNA binding at the 30 untranslated region (UTR) of
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REEP1 causing spastic paraplegia 31 (SPG31 [MIM:
610250]).25 The last variant, TSC2 p.Glu75Lys
(RR5 3.3), is a variant of unknown significance for
tuberous sclerosis (TSC2 [MIM: 613254]).
REEP1 c.6061 43G>T was found in a PPMS
patient (65-0008) with spastic paraparesis from our
WGS discovery cohort and in 2 additional PPMS
patients (52-0139 and 52-1859) with a progressive spinal
cord syndrome in our Phase 1 replication genotyping.
This variant was also found in 2 RMS patients (21-
0003, MSGENE02-528) and 2 controls (9961-50050,
9961-51000901) in our Phase 2 replication genotyping
at a frequency comparable to the ExAC European cohort.
KIF5A c.C1082T p.Ala361Val was found in a PPMS
patient (02-0069) with spastic paraparesis from our dis-
covery cohort and was also found in 1 RMS patient
(MSGENE02-539) in our Phase 2 replication genotyping
at a lower frequency compared to that observed in PPMS
patients. MLC1 c.274C>T p.Pro92Ser was found in a
PPMS patient (04-1225) with brain-predominant disease
TABLE 3. MS Phenocopy Variants Selected for Phase 1 and Phase 2 Replication
Genetic Variant
Number of Individuals Carrying a
Heterozygous Mutation
Minor Allele
Frequency (%)a
Risk vs
ExAC EUR
Discovery
Cohort (WGS)
Phase 1 Repli-
cation
(OpenArray)
Phase 2 Replication
(targeted typing)
Gene Variantb Disorder
(inheritance)c
38
PPMS
81
CTRLS
411
PPMS
460
RMS
335
PPMS
2589
RMS
1000
CTRLS
All
PPMS
All
RMS
All
CTRLS
ExAC
EUR
RR for
PPMS
KIF5A p.A361V SPG10 (AD) 1 0 0 0 0 1 0 0.064 0.016 0.000 0.003 23.3
TSC2 p.E75K TSe (AD) 1 0 0 0 0 0 0 0.064 0.000 0.000 0.019 3.3
MLC1 p.P92S MLC (AR) 1 0 0 0 0 4 0 0.064 0.066 0.000 0.034 1.9
REEP1 c.606
143G>T
SPG31 (AD) 1 0 2 0 0 2 2 0.191 0.033 0.093 0.115 1.7
SCN9A p.W1538R PE (AD) 1 0 6 3 Not selected for Phase 2: 0.67 0.33 0.00 0.173 3.9
HPD p.I335M TYRSN3 (AR) 1 0 3 3 Variant was found in at least 0.33 0.33 0.00 0.158 2.1
CACNA1A p.P897R EA2 (AD) 1 0 1 2 one RMS patient in Phase 1. 0.22 0.22 0.00 0.141 1.6
DCTN1 p.T1249I ALS (AD) 1 0 3 4 0.22 0.43 0.00 0.416 0.5
D2HGDH p.A426T D-2-HGA (AR) 3 0 7 3 0.89 0.33 0.00 1.101 0.8
ADAR p.P193A AGS (AR, AD) 1 0 1 1 0.22 0.11 0.00 0.281 0.8
NOTCH3 p.S497L CADASIL (AD) 2 0 7 4 0.67 0.43 0.00 1.395 0.5
SLC6A5 p.T690T HKPX3e (AD) 1 0 0 4 0.11 0.43 0.00 0.271 0.4
NF1 p.D176E NF1 (AD) 1c 0 2 5 Not selected for Phase 2: 0.24 0.54 0.00 0.512 NA
TSC2 p.L1423L TSe AD) 1c 0 0 0 CGI genotypes not 0.00 0.00 0.00 0.423
LRRK2 p.E334K PD (AD) 1c 0 0 0 validated on OA 0.00 0.00 0.00 0.484
aMinor allele frequencies (MAFs) are calculated for 784 PPMS, 3,049 RMS, and 1,081 control subjects for the top four candidate variants. For all
other variants, MAF is calculated for 449 PPMS, 460 RMS, and 81 control subjects. The ExAC European (including Finnish) cohort was used as
the reference to calculate relative risk for candidate variants.
b“c” denotes coding DNA sequence position; “p” denotes protein amino acid position. Only the variant corresponding to the primary transcript
according to ExAC is provided.
cPhenocopy disorder abbreviations: SPG5 spastic paraplegia; TS5 tuberous sclerosis; MLC5megalencephalic leukodystrophy with subcortical
cysts; PE5 primary erythromelalgia; TYRSN35 tyrosinemia type 3; EA25 episodic ataxia 2; ALS5 amyotrophic lateral sclerosis; D-2-HGA5D-
2-hydroxyglutaric aciduria; AGS5Aicardi-Goutie`res syndrome; CADASIL5 cerebral autosomal-dominant arteriopathy with subcortical infarcts
and leukoencephalopathy; HKPX35 hyperekplexia 3; NF15 neurofibromatosis type 1; PD5 Parkinson’s disease.
dThese variants were not validated during Phase 1 replication genotyping.
eThese variants have not yet been reported to be pathogenic in this disorder.
J_ID: ANA Customer A_ID: ANA25263 Cadmus Art: ANA25263 Ed. Ref. No.: 17-1506.R3 Date: 23-June-18 Stage: Page: 6
ID: jwweb3b2server Time: 20:39 I Path: //chenas03.cadmus.com/Cenpro/ApplicationFiles/Journals/Wiley/ANA#/Vol00000/180111/Comp/APPFile/JW-ANA#180111
ANNALS of Neurology
6 Volume 00, No. 0056 Volume 84, No. 1
l gy
from our discovery cohort. Of note, the MLC1 variant was
also found in 4 RMS patients (52-1463, 05-0032, 60-
0354, and 60-0362) with the same frequency as that
observed in PPMS patients, and in 0 controls, in our Phase
2 replication genotyping. Last, TSC2 c.G223A p.Glu75Lys
was found in a PPMS patient (60-0385) with a mild dis-
ease course from our discovery cohort. These results are
summarized in Table 3, and detailed clinical information
is provided in TableT4 4 and Tables S2 and S3.
Given that two of the top four genes identified by
WGS (REEP1 and KIF5A) are associated with progressive
spinal cord injury, we hypothesized that PPMS patients
may be generally enriched for deleterious mutations in
genes that associate with the hereditary spastic paraple-
gias. Spastic paraplegias are a rare group of conditions
that cause degeneration of motor axons in the corticospi-
nal tract resulting in progressive leg weakness and spastic-
ity,12 providing a plausible basis for phenotypic mimicry
(ie, phenocopy) with MS. To test this hypothesis, we
examined 48 PPMS patients of European ancestry who
satisfied 2010 International Panel Criteria and 100
matched controls genotyped using the custom MS (ie,
replication) chip, which includes more than 240,000
exonic variants. We extracted 169 rare, functionally dele-
terious, and potentially pathogenic variants within the 41
genes known to cause spastic paraplegias12,25–29 (Table
S4). Interestingly, PPMS patients harbored, on average,
significantly more variants (0.29 per individual) in these
genes than did controls (0.11), and the risk for PPMS
increased with the number of potentially pathogenic var-
iants (RR5 2.65; 95% confidence interval [CI], 1.18–
5.96; likelihood ratio [LR], p5 0.028).
To evaluate the likelihood of finding an enrichment
of spastic paraplegia variants in PPMS patients by
chance, we randomly permuted PPMS and healthy con-
trol status in our discovery cohort 10,000 times and
TABLE 4. PPMS Patients Who Carry a Reported Phenocopy Variant
Clinical characteristics
2010 International Panel Criteriaa Genetic Variant
ID Sex Age at
Onset
Progressive
course
Positive CSF
(elevated IgG
index, OCBs)
Brain
MRI
Spine
MRI
Gad1 Meets
criteria
Gene Disorder
(inheritance)
Reported
Variantb
Typec Platformd
020069 F 37 1 ND 1 1 - 1 KIF5A SPG10
(AD)
p.A361V mis CGI
041225 F 51 1 1 (1 ,1 ) 1 - - 1 MLC1 MLC
(AR)
p.P92S mis CGI
650008 F 50 1 1 (1 ,1 ) 1 1 - 1 REEP1 SPG31
(AD)
c.606
1 43G>T
30 CGI
650084 F 48 1 1 (-,1 ) 1 1 - 1 SPG7 SPG7
(AR,AD)
c.1552
1 1G>T
ss MS
chip
700019 F 61 1 1 (1 ,1 ) 1 1 1 1 SPG7 SPG7
(AR,AD)
p.A510V mis MS
chip
520139e F 26 1 1 - 1 - 1 REEP1 SPG31
(AD)
c.606
1 43G>T
30 OA
521859e M 57 1 ND 1 ND - - REEP1 SPG31
(AD)
c.606
1 43G>T
30 OA
a2010 International Panel Criteria includes (1) progression since onset without relapses and (2) two of the following three criteria: positive CSF
(elevated IgG index or oligoclonal bands), brain lesions consistent with MS, and spinal cord lesions consistent with MS. “1” denotes satisfies crite-
ria, “–” denotes does not satisfy criteria, “ND” denotes test was not done. GAD denotes gadolinium enhancement on at least one magnetic reso-
nance imaging brain or spinal cord.
b“c” denotes coding DNA sequence position; “p” denotes protein amino acid position. Only the variant corresponding to the primary transcript
according to ExAC is provided.
cVariant types: mis5missense; ss5 splice site; 305 30UTR.
dGenotyping platforms: CGI5WGS via Complete Genomics Inc.; MS chip5MS replication chip; OA5OpenArray.
ePPMS patients from Phase 1 replication cohort. CSF for patient 520139, performed at the NIH in 1977, was reported to be consistent with MS;
however, results were not available.
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calculated the enrichment of HSP-related variants deter-
mined using the same criteria. Strikingly, the 2.7-fold
enrichment of spastic paraplegia variants in PPMS was
greater than in 98.5% of case-control permutations
(p5 0.015), suggesting that the observed enrichment was
unlikely attributed to chance (FigF2 2). Sensitivity analysis
demonstrated a persistent enrichment of HSP variants in
PPMS after applying various in silico predicted pathoge-
nicity criteria (Table S5). No significant enrichment was
detected in 48 genes affecting inherited leukodystro-
phies,11 166 genes affecting other Mendelian disorders
that involve the CNS,32 or in the 200 genes associated
with MS in a recent GWAS meta-analysis.16 Whereas we
observed a trend toward enrichment of variants in 48
genes affecting inherited leukodystrophies, this was not
significant (RR5 1.9; 95% CI, 0.9–4.2; LR, p5 0.091).
A summary of discovery cohort PPMS patients who carry
a reported MS phenocopy variant is shown in Table 4.
To replicate our finding that PPMS patients are
enriched for mutations in genes that cause spastic para-
plegias, we examined three additional cohorts of Euro-
pean ancestry genotyped on the MS replication chip.
Using the same variant selection criteria as described pre-
viously, we detected an enrichment of HSP-related muta-
tions in 122 PPMS patients (0.3 variants per individual)
recruited through NARCOMS compared to 321 controls
(0.12; RR5 2.56; 95% CI, 1.64–4.01; LR,
p5 6.03 1024), as well as in an Australian cohort of 57
PPMS patients (0.26) compared to 410 controls (0.14;
RR5 1.83; 95% CI, 1.00–3.35; LR, p5 0.049). No
enrichment was observed in an Italian cohort of 87
PPMS patients (0.08) compared to 156 controls (0.1;
RR5 0.84; 95% CI, 0.35–2.02; p5 0.8). Meta-analysis
of the discovery and three replication cohorts confirmed
a significant enrichment of potentially pathogenic HSP
mutations in 315 PPMS patients compared to 987 con-
trols (RR5 1.95; 95% CI, 1.27–2.98; random-effects
model, p5 0.002; Fig F33).
To determine whether the enrichment of variants
observed in spastic paraplegia genes was unique to PPMS
patients or whether this also contributes to the risk for
SPMS, we examined genotypes from SPMS (n5 587)
and RMS (n5 2,248) patients of European ancestry
from the four cohorts in our meta-analysis. On average,
PPMS (n5 315) patients harbored a significantly higher
number of spastic paraplegia variants (0.23 per individ-
ual) compared to RMS patients (0.14; n5 2,248; mean
difference [MD]5 0.10; 95% CI, 0.06–0.14; t test,
FIGURE 2: Burden of spastic paraplegia mutations in PPMS.
(A) Forty-eight PPMS patients genotyped on the MS replica-
tion chip are enriched for rare (MAF<1% in public data
sets), functionally deleterious (missense and splice site), and
potentially pathogenic (CADD score,>10; PhyloP conserva-
tion, p<0.01) variants in 41 genes known to cause spastic
paraplegias, and the relative risk for PPMS increases with
the number of HSP-related variants carried by an individual
(cases mean50.29; controls mean50.11; RR52.7; logistic
regression, p50.028). (B) Random permutation of PPMS
case and control status shows that the 2.7-fold enrichment
of pathogenic variants in 41 HSP-related genes is greater
than in 98.5% of 10,000 permutations (p50.015).
HSP5hereditary spastic paraplegia; LR5 likelihood ratio;
MAF5minor allele frequency; MS5multiple sclerosis; Phy-
loP5phylogenetic conservation p value; PPMS5primary
progressive multiple sclerosis; RR5 risk ratio.
FIGURE 3: Meta-analysis of HSP-related mutations across
multiple cohorts. Examination of 314 PPMS patients and
987 controls genotyped on the MS Replication Chip across
four cohorts (UCSF, NARCOMS, Australian, and Italian) con-
firmed the observation that PPMS patients harbor signifi-
cantly more potentially pathogenic HSP mutations
compared to controls (RR51.95; random effects model,
p50.002). HSP5hereditary spastic paraplegia; MS5multi-
ple sclerosis; NARCOMS5North America Research Commit-
tee on Multiple Sclerosis; PPMS5primary progressive
multiple sclerosis; RR5 risk ratio; UCSF5University of Cali-
fornia San Francisco; RE5 random effects.
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p5 9.63 1024) and compared to controls (0.12;
n5 987; MD5 0.11; 95% CI, 0.05–0.17;
p5 3.83 1024). Interestingly, SPMS patients (n5 587)
also harbored a higher number of spastic paraplegia var-
iants (0.17 per individual) compared to RMS patients
(0.14; n5 2,248; MD5 0.04; 95% CI, 0.00–0.07;
p5 0.048) and compared to controls (0.12; n5 987;
MD5 0.05; 95% CI, 0.01–0.09; p5 0.018). By con-
trast, no significant enrichment was found in RMS
patients compared to controls (MD5 0.01; 95% CI, –
0.02 to 0.04; p5 0.4; FigF4 4). Whereas we observed a
trend toward enrichment of HSP-related variants in
PPMS patients (0.23) compared to SPMS patients
(0.17), this was not significant (MD5 0.06; 95% CI, –
0.01 to 0.12; p5 0.07). These results suggest that the
enrichment of spastic paraplegia variants is unique to
patients with a progressive disease course and is not pre-
sent in all forms of MS.
We subsequently hypothesized that the risk for
developing a progressive form of MS is related to the
accumulation of rare deleterious variants that directly
affect degenerative neurological disorders, and this risk is
independent of the genetic burden that confers suscepti-
bility for MS. To test this hypothesis, we calculated the
MS Genetic Burden (MSGB) in PPMS (n5 170),
SPMS (n5 425), RMS (n5 1516), and healthy subjects
(n5 421) from our UCSF and NARCOMS MS replica-
tion chip cohorts. We found that, on average, MS
patients (n5 2,111) have a higher MSGB (mean5 22.7)
compared to healthy controls (21.7; (MD5 1.0; 95%
CI, 0.86–1.13; p5 2.23 10242). We did not detect a
significant difference in MSGB between PPMS (22.9),
SPMS (22.8), and RMS (22.7) patients (PPMS versus
RMS, MD5 0.15; 95% CI, –0.06 to 0.37; p5 0.17;
SPMS versus RMS, MD5 0.07; 95% CI, –0.07 to 0.21;
p5 0.34; PPMS versus SPMS, MD5 0.8; 95% CI, –
0.16 to 0.33; p5 0.49). Importantly, we observed no sig-
nificant difference between PPMS patients who carry a
HSP variant (22.9; n5 44) and those who do not (22.9;
n5 126; MD5 0.02; 95% CI, –0.55 to 0.48; p5 0.95).
Likewise, we detected no difference between SPMS
patients who carry a HSP variant (23.0; n5 62) and
those who do not (22.7; n5 363; MD5 0.22; 95% CI,
–0.14 to 0.58; p5 0.23). These results suggest that rare
HSP-related variants modulate the risk for developing a
progressive disease course independent of the overall
genetic burden that confers risk for developing MS.
Discussion
Although many disorders resemble MS clinically and radio-
graphically, we are unaware of previous reports associating
Mendelian disorder genes in PPMS. Systematic review of
clinical records indicates that patients who carried a MS
phenocopy-related mutation were not misdiagnosed with
PPMS, but rather carry clinical characteristics of both
PPMS and the phenocopy disorder. Specifically, the PPMS
patients with pathogenic mutations in REEP1 and KIF5A
have demyelinating-appearing lesions on magnetic reso-
nance imaging. Cerebrospinal fluid (CSF) was obtained in
2 of 3 REEP1 carriers and both had elevated intrathecal
gammaglobulin synthesis. CSF was not obtained in the
KIF55A pA361V carrier. Carriers of these phenocopy
mutations experienced progressive spastic paraparesis typical
of both PPMS and HSP. Additional studies are needed to
better understand the impact of these MS phenocopy
mutations on disease severity in PPMS.
Furthermore, to our knowledge, this is the first
study to report that PPMS patients are enriched for
mutations in genes that cause spastic paraplegias. We
show that the enrichment of HSP-related variants in
PPMS is significantly higher than expected by chance, is
validated in meta-analysis across multiple cohorts, and is
not present in RMS patients. Importantly, SPMS patients
FIGURE 4: HSP-related mutation burden in PPMS, SPMS,
RMS, and controls. Examination of 314 PPMS, 2,248 RMS,
587 SPMS, and 987 control subjects from four cohorts
(UCSF, NARCOMS, Australian, and Italian) showed that
PPMS patients (0.23 variants per individual) on average har-
bored a significantly higher number of potentially patho-
genic HSP-related mutations compared to RMS (0.14) and
controls (0.12; t test, p53.831024 for PPMS vs controls;
p59.631024 for PPMS vs RMS). Moreover, SPMS patients
(0.17), on average, also harbored a higher number of HSP-
related mutations compared to RMS (0.14) and controls
(0.12; p50.018 for SPMS vs controls, p50.048 for SPMS
vs RMS). Importantly, no significant enrichment was
detected in RMS patients compared to healthy controls
(p50.4). HSP5hereditary spastic paraplegia; NS5not sig-
nificant; PPMS5primary progressive multiple sclerosis;
RMS5 relapsing multiple sclerosis; SPMS5 secondary pro-
gressive multiple sclerosis.
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also harbor a detectable enrichment of spastic paraplegia
mutations, suggesting that there might be a shared
genetic susceptibility to progressive forms of MS, and
that carrying such variants might increase the risk for
developing secondary progression after an earlier
relapsing-onset course. Last, we observe no significant
difference in the burden of common MS susceptibility
variants in PPMS and SPMS patients who carry a spastic
paraplegia variant compared to those who do not. These
findings suggest that rare mutations in genes that cause
degenerative neurological disorders contribute to a pro-
gressive disease course, and this effect is independent of
the burden of common MS susceptibility variants that
influences the risk for developing MS.
We acknowledge a number of limitations. First,
although we comprehensively examined pathogenic
SNVs, which are better documented in literature, we did
not analyze CNVs, structural variants, or intergenic regu-
latory mutations that might also be pathogenic. Second,
the size of the discovery WGS cohort was limited by the
high cost of genome sequencing. After performing WGS
in the pilot PPMS cohort, we subsequently devoted
resources to independent replication rather than addi-
tional sequencing. Third, we did not identify pathogenic
SNVs on the sex chromosomes, and thus our results do
not explain the difference in gender distribution between
PPMS (equally affects males and females) and RMS
(female predominant). Fourth, although we used an
expert-curated and experimentally validated list of spastic
paraplegia genes, a more comprehensive gene list will
emerge as additional HSP-related loci are discovered.
Therefore, our analysis might underestimate the preva-
lence of such mutations in progressive forms of MS.
Fifth, the enrichment of spastic paraplegia mutations in
PPMS patients was not detected in the Italian cohort.
The genetic variation of Italian Europeans can be distin-
guished from that of other European populations,8 and
known common pathogenic spastic paraplegia mutations
in this population33–35 were not captured on the MS
replication chip. Last, whereas clinical genetic testing
may be useful in refining a diagnosis when it is in ques-
tion, the utility of genetic testing in PPMS patients is
currently limited given the lack of disease-modifying
treatments for the Mendelian genetic variants that might
contribute to a progressive disease course.
Proposed mechanisms for PPMS pathogenesis include
compartmentalized leptomeningeal inflammation behind a
relatively intact blood–brain barrier, oxidative stress driving
mitochondrial injury, chronic microglial activation causing
oligodendrocyte dysfunction and axonal injury, and age-
related iron accumulation.36–40 By examining MS pheno-
copy mutations, this study identified genes encoding
neuroaxonal proteins (KIF5A), mitochondrial function
(REEP1, SPG7), and astrocyte osmoregulation (MLC1),
supporting the hypothesis that genetic variation contributes
to progressive neuronal and glial dysfunction in PPMS.
However, our approach does not comprehensively assess all
proposed mechanisms for PPMS, including complex local
autoimmune and glial-mediated pathways that do not
manifest as monogenic disorders.
KIF5A c.C1082T p.Ala361Val (a reported domi-
nant mutation for SPG1027) was found in a PPMS
patient (02-0069) from our WGS discovery cohort. We
considered the presence of this variant to be responsible
for a progressive myelopathy characteristic of SPG10,
highlighting a potential MS phenocopy. This variant was
previously reported in a SPG10 patient with adult-onset
(age 35) spastic paraparesis from an affected family span-
ning 4 generations.27 KIF5A encodes an axonal motor
protein responsible for anterograde transport. Reduced
expression of KIF5A has been observed in MS white
matter lesions,41 and some SPG10 patients have
demyelinating-appearing lesions in the spinal cord.26
Whereas KIF5A is located in the MS susceptibility locus
CYP28B1-OS9, the top SNP in this region (rs701006)
does not influence KIF5A expression,42 and there is no
clear linkage between this common MS susceptibility var-
iant and the rare KIF5A variant (rs121434444).14 We
hypothesize that disruption to axonal transport may be,
in part, responsible for neurodegeneration and spinal
cord injury in progressive forms of MS; however, addi-
tional studies are needed to confirm this association and
to understand its functional impact.
REEP1 c.6061 43G>T (a reported dominant vari-
ant for SPG3125) was found in a PPMS patient (65-
0008) from our discovery cohort and 2 PPMS patients
(52-0139, 52-1859) from our replication cohorts.
Reported SPG31 patients who carried this variant had
heterogeneous clinical characteristics, ranging from mild
paraparesis to severe tetraparesis with bulbar dysfunction.
Functional studies show that REEP1 facilitates
mitochondrial-endoplasmic reticulum (ER) interactions,
and altered ER-mitochondrial contacts cause intracellular
Ca21 overload resulting in axonal injury. We found addi-
tional evidence for the role of mitochondrial dysfunction
in PPMS by identifying reported pathogenic mutations
for spastic paraplegia 7 (SPG7 [MIM: 607259])12,43–46
in two PPMS patients (70-0019, 65-0084) from our MS
chip discovery cohort (Table 4). SPG7 encodes the mito-
chondrial protein paraplegin, and mutations in this gene
cause complex spastic paraplegia attributed to complex I
deficiency and increased sensitivity to oxidative stress.47
These findings provide evidence for a pathogenic role of
REEP1 and SPG7 in PPMS, and supports the hypothesis
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that mitochondrial dysfunction and diminished tolerance
to oxidative stress may contribute to progressive myelop-
athy in PPMS.
The MLC1 c.274C>T p.Pro92Ser variant (a
reported recessive and isolated heterozygous mutation in
MLC,31 a leukodystrophy characterized by myelin swell-
ing and cystic changes arising from dysfunction of
MLC1 cell junction proteins on astrocytic foot processes)
was found in a PPMS patient (04-1225) from our WGS
discovery cohort. Of note, this variant was also found in
4 RMS patients (52-1463, 05-0032, 60-0354, and 60-
0362) with the same frequency as that observed in
PPMS patients, and in 0 controls, in our Phase 2 replica-
tion genotyping. This variant is rare (MAF 0.03%) and,
to our knowledge, has not been examined through
GWAS. Neuropathology studies show that active MS
lesions have reduced staining for perivascular astrocytic
MLC1, whereas chronic lesions demonstrate upregulation
of MLC1 attributed to astrogliosis.48,49 Astrocytes are
hypothesized to play a role in MS disease progression
through participation in the innate immune system, pro-
duction of cytotoxic factors, and inhibition of remyelina-
tion by forming glial scar.50 Despite these observations,
the exact role of MLC1 in MS pathogenesis remains
unclear. Given that MLC1 p.Pro92Ser has been reported
in leukodystrophy patients and is well characterized in
functional studies, we hypothesize that this MLC1 variant
affects white matter injury through astrocyte-mediated
osmoregulatory dysfunction in both PPMS and RMS
patients, albeit with incomplete penetrance and variable
expressivity.
TSC2 p.Glu75Lys was found in a PPMS patient
(60-0385) from our WGS discovery cohort. White mat-
ter lesions in tuberous sclerosis are often caused by
abnormal cortical development or neuronal migration
rather than demyelination.51 Because of the lack of
reported pathogenic cases, we consider TSC2 p.Glu75Lys
a variant of uncertain significance without a clear role in
PPMS pathogenesis.
Understanding the role of phenocopies in PPMS has
important clinical implications. The finding that PPMS
patients are enriched for HSP-related mutations that cause
progressive axonal injury is consistent with the observation
that the most common clinical presentation in PPMS is a
progressive spastic paraparesis3,52,53 and might help explain
why these patients respond poorly to immunomodulatory
therapies. Moreover, carrying a pathogenic mutation for a
MS phenocopy disorder does not cause MS, but rather
modulates the disease course through mechanisms indepen-
dent of immune-mediated pathways implicated by reported
MS susceptibility loci. Larger studies are needed to identify
additional phenocopy disorders that might contribute to a
progressive disease course in MS. Longitudinal studies are
needed to examine the predictive value of rare phenocopy
variants on transition to secondary progression in patients
with relapsing-onset disease. Last, translational studies are
required to develop disease-modifying therapies for spastic
paraplegias and other Mendelian disorders that share clini-
cal features with MS. These efforts are instrumental for
developing effective treatments that slow and prevent dis-
ability in patients with progressive forms of MS.
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